Ashley Renee Roy, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 221 Orchard Hill Rd, Pomfret Center, CT 06259 Phone: 401-528-9696 |
News Archive
Results from an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with a targeted therapy known as rucaparib, resulting in recent FDA approval.
Maryland House leaders on Wednesday proposed a $1-per-pack cigarette tax increase to extend health insurance coverage to at least 250,000 uninsured state residents, the Washington Post reports.
Two recent studies led by researchers from the University of Minnesota Medical School add new evidence to the impact of how drug price increases affect U.S. patients and the overall cost of health care.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
› Verified 6 days ago